AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Rheumatoid Arthritis (RA)
Idiopathic Inflammatory Myopathies (IIMs)
Systemic Sclerosis (SSc)
Rheumatoid Arthritis (RA
IIM
Myositis
Scleroderma
Sjogren Syndrome
Sjogrens Disease

Interventions

DRUG: Allogeneic NK Cells

Sponsor

Artiva Biotherapeutics, Inc.